Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

BMC Neuroscience

Christian Hölscher¹  Kerry Hunter² 

[1] University of Ulster, School of Biomedical Sciences, Cromore Road, Coleraine BT52 1SA, Northern Ireland;School of Biomedical Sciences, Ulster University, Coleraine, UK

关键词: Stem cells;    Neuroprotection;    Diabetes;    Parkinson's disease;    Alzheimer disease;   

Others  :  1170794
DOI  :  10.1186/1471-2202-13-33

 received in 2011-12-07, accepted in 2012-03-23,  发布年份 2012

【 摘 要 】

Background

Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-lasting analogues of the GLP-1 incretin hormone and are currently available to treat diabetes. They facilitate insulin signalling via the GLP-1 receptor (GLP-1R). Numerous in vitro and in vivo studies have shown that GLP-1 analogues have a range of neuroprotective properties. GLP-1Rs are expressed in the hippocampal area of the brain an important site of adult neurogenesis and maintenance of cognition and memory formation. Therefore, if GLP-1 analogues can cross the blood brain barrier, diffuse through the brain to reach the receptors and most importantly activate them, their neuroprotective effects may be realized.

Results

In the present study we profiled the GLP-1 receptor agonists liraglutide (Victoza) and lixisenatide (Lyxumia). We measured the kinetics of crossing the blood brain barrier (BBB), activation of the GLP-1R by measuring cAMP levels, and physiological effects in the brain on neuronal stem cell proliferation and neurogenesis. Both drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol/kg bw ip.) when measured 30 min post-injection and at 2.5-25 nmol/kg bw ip. 3 h post-injection. Lixisenatide also enhanced neurogenesis in the brain. Liraglutide crossed the BBB at 25 and 250 nmol/kg ip. but no increase was detectable at 2.5 nmol/kg ip. 30 min post-injection, and at 250 nmol/kg ip. at 3 h post-injection. Liraglutide and lixisenatide enhanced cAMP levels in the brain, with lixisenatide being more effective.

Conclusions

Our results suggest that these novel incretin analogues cross the BBB and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.

【 授权许可】

   
2012 Hunter and Hölscher; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
• [2]Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705.
• [3]Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK: The effect of exenatide re-exposure on safety and efficacy. Peptides 2009, 30(9):1771-1774.
• [4]Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45(2):101-113.
• [5]Christensen M, Knop FK, Vilsboll T, Holst JJ: Lixisenatide for type 2 diabetis mellitus. Expert Opin Investig Drugs 2011, 20(4):549-557.
• [6]Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.
• [7]Ristow M: Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004, 82(8):510-529.
• [8]Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y: Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011, 77(12):1126-1134.
• [9]Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM: Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006, 9(1):13-33.
• [10]Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C: Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010, 31(2):224-243.
• [11]Holscher C: Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5:109-117.
• [12]Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP: Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7(11):2294-2300.
• [13]Hamilton A, Holscher C: Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009, 20:1161-1166.
• [14]Gengler S, McClean P, McCurtin R, Gault V, Holscher C: Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010. DOI:10.1016/j.neurobiolaging.2010.1002.1014
• [15]Wang XH, Li L, Holscher C, Pan YF, Chen XR, Qi JS: Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010, 170(4):1239-1248.
• [16]McClean P, Parthsarathy V, Faivre E, Hölscher C: The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594.
• [17]Kastin AJ, Akerstrom V: Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27(3):313-318.
• [18]Li Y, Duffy K, Ottinger M, Ray B, Bailey J, Holloway H, Tweedie D, Perry T, Mattson M, Kapogiannis D, et al.: GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010, 19:1205-1219.
• [19]Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, et al.: Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011, 60(9):2397-2406.
• [20]During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al.: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9(9):1173-1179.
• [21]Hamilton A, Patterson S, Porter D, Gault VA, Holscher C: Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 2011, 89(4):481-489.
• [22]Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45(10):1410-1415.
• [23]Perry T, Greig NH: Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005, 2(3):377-385.